CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
18/04/2023
Voltar para busca
Dado oficial do USPTO
POLYTAXEL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
42
Atualização mais recente
18/04/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
18/07/2019
Data de registro
28/06/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/06/2022
Última transação
28/06/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Seoul, KR
Examinador
VALLILLO, MELISSA
Unidade examinadora
L50
Localização atual
TMEG LAW OFFICE 105
Titulares e representantes
Titulares
CnPharm Co., Ltd.
Representantes
Samuel S. Lee Procopio, Cory, Hargreaves & Savitch LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of pancreatic tumors; pharmaceutical agents for the treatment of disorders in sensory organs; thyroid and para-thyroid hormone preparations; medicinal tonics for the treatment of pancreatic tumors; oral contraceptive pills; antiemetics; local anesthetics; bronchodilating preparations; anti-cough drops; androgen preparations; pituitary hormone preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents for use in regulating metabolism; vaccines against flu; chilblain preparations; pharmaceutical preparations for headache; anaesthetics; pharmaceutical for use in the treating disorders of the peripheral nervous system; pharmaceutical preparations for immunity adjustment; nutritive substances for microorganisms for medical purposes; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations for treating disorders of the urogenital organs; vitamin preparations; pharmaceutical preparations for the treatment of bone diseases; anti-inflammatory and antipyretic preparations; pharmaceutical agents for treating disorders of the digestive organs; pharmaceutical preparations for the treatment of cardiovascular disorders; nervines; ophthalmic preparations; allergy medications; chemicopharmaceutical preparations for the treatment of pancreatic disorders; medicines for the treatment of gastrointestinal diseases; mineral injection preparations featuring vitamin supplements for medical purposes; antioxidants for medical purposes; haematogen; pharmaceutical preparations for tumor treatment; multivitamin preparations; suppositories; pharmaceutical preparations for use in the treatment of disorders of the central nervous system; pharmaceutical preparations for diagnosis of cancer; sedatives; analgesics; vaginal washes for medical purposes; pharmaceutical preparations for treating asthma; medicines for treating tooth pain; hemorrhoid preparations; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; vaccines against pneumococcal infections; dermatological pharmaceutical products; contraceptive preparations; antihypertensives; anti-uric preparations; anti-diabetic pharmaceuticals; pharmaceutical preparations for treatment of hemorrhoids; antibiotic preparations; antibiotics; anti-cancer preparations; anti-cancer treatment supplements; antidepressants; anticoagulants; antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; febrifuges; vasoconstrictors; hypoglycemic agents; blood solvent being preparations for treating blood disorders; pharmaceutical preparations for treating disorders of the respiratory organs; respiratory stimulant preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for treating respiratory diseases and asthma; mixed vitamin preparations; preparations for the treatment of burns; disinfectants for chemical toilets; chemotherapeutics; preparations for treatment of hepatitis; preparations for treating colds; preparations for the treatment of hyperlipidemia; preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of osteoporosis; preparations for the treatment of osteoporosis; injectable pharmaceuticals for treatment of anaphylactic reactions; pharmaceutical preparations for treating halitosis; nausea treatment preparations; antiulcerants; pharmaceutical preparations for the treatment of musculoskeletal disorders; preparations for the treatment of muscle fatigue; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for the treatment of rhinitis; pharmaceutical products for the treatment of bone diseases; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; pharmaceutical preparations for the treatment of cancerous cells; medicines for treating intestinal disorders; cardiovascular treatment preparations; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for treating allergies; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; medicated preparations for the treatment of mouth disorders; transdermal patches for medical treatment of nausea; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of gout; drug delivery agents in the form of dissolvable filmscoatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents consisting of compounds that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements
Publicações
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/04/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
18/04/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/04/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/04/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
18/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
28/06/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
28/06/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/04/2022
PUBO
PUBLISHED FOR OPPOSITION
12/04/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
11/04/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
05/04/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
28/03/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/03/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
21/03/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
14/03/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
07/03/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/03/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
28/02/2022
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
30/07/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
13/10/2020
GNSL
LETTER OF SUSPENSION E-MAILED
13/10/2020
CNSL
SUSPENSION LETTER WRITTEN
13/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/10/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/10/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/05/2020
GNRT
NON-FINAL ACTION E-MAILED
19/05/2020
CNRT
NON-FINAL ACTION WRITTEN
19/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/04/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/04/2020
ALIE
ASSIGNED TO LIE
16/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/04/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/11/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/11/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/10/2019
GNRT
NON-FINAL ACTION E-MAILED
10/10/2019
CNRT
NON-FINAL ACTION WRITTEN
10/10/2019
DOCK
ASSIGNED TO EXAMINER
07/10/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/07/2019
NWAP
NEW APPLICATION ENTERED
22/07/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace POLYTAXEL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.